Medicamen Organics Ltd.

Medicamen Organics Ltd.

NNSE:MEDIORG
24.55
INR
-0.90
(-3.54%)
Medicamen Organics Ltd.
NSE:MEDIORG
(National Stock Exchange of India)

Recent

price

24.55

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
2026
TTM
INR
21.41
17.93
18.93
21.6
34.63
20.52
- -
Revenue per Share
0.25
0.09
0.83
2.24
3.67
-3.64
- -
Basic EPS, GAAP
-1.02
-0.49
-0.75
-3.43
-6.34
-5.74
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
6.38
6.85
7.68
13.04
25.75
24.55
13.04
Book Value per Share
6.37
6.83
7.66
13.03
25.74
24.1
13.03
Tangible Book Value per Share
12
12
12
12
11
11
10
Basic Weighted Avg Shares
250
210
221
253
382
226
- -
Sales/Revenue/Turnover
5.23
2.47
5.33
16.3
15.32
-20.54
- -
Operating Margin (%)
7
7
7
7
6
6
- -
Depreciation Expense
3
1
10
26
40
-40
- -
Net Income, GAAP
39.24
60.27
28.71
40.85
25.47
- -
- -
Effective Tax Rate (%)
1.19
0.48
4.38
10.38
10.6
-17.76
- -
Profit Margin (%)
-23
-21
-10
57
183
151
57
Working Capital
6
6
3
2
2
10
2
LT Debt
75
80
90
153
305
286
153
Total Equity
- -
1.58
7.17
12.22
10.2
- -
- -
Return on Invested Capital (%)
- -
1.55
7.03
12.29
12.52
- -
- -
Return on Capital (%)
- -
1.31
11.41
21.65
17.83
-13.66
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Mar'24
ST Debt
125
LT Borrowings
2
LT Finance Leases
- -
Preferred Equity and Hybrid Capital
- -
Shares Outstanding
12
Market Capitalization
- -

Working Capital

INR

•

in mil. unless spec.
Mar'24
Total Current Assets
273
Cash, Cash Equivalents & STI
6
Accounts Receivable, Net
167
Inventories
61
Total Current Liabilities
216
Payables & Accruals
- -
ST Debt
125
Deferred Revenue
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
36.57%
-6.21%
Free Cash Flow
- -
84.75%
-9.4%
Net Income, GAAP
- -
163.12%
-199.32%
Sales/Revenue/Turnover
- -
2.76%
-40.74%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
253
2025
- -
- -
382
2026
- -
- -
226

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2.24
2025
- -
- -
3.67
2026
- -
- -
-3.64

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Medicamen Organics Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and distribution of generic pharmaceutical dosage forms, including tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders, as well as nutraceuticals and food supplements such as protein powders under brands like Soyagrowth and Nusowin, and Glucovita Bolts for Wipro Enterprises. The company operates two WHO-GMP certified plants in Haridwar, with Plant 1 dedicated to iron and folic acid tablets at a capacity of 9 million tablets per day and Plant 2 handling non-beta lactam tablets, capsules, oral liquids, and ointments; it serves as a contract and third-party manufacturer for government institutions and private clients including Morepen, Anglo French, Elder, Bestochem, Shreya Lifesciences, Win Medicare, Jagsonpal Drugs, and international partners like Mission Pharma and Knoll. Its product portfolio encompasses over 84 items across categories such as antibacterials, anti-diarrheals, antifungals, anti-malarials, anti-diabetics, proton pump inhibitors, antihistamines, antihypertensives, anti-lipidemic drugs, antiparasitics, multivitamins, multiminerals, and non-steroidal anti-inflammatory drugs (NSAIDs). Founded in 1995 and headquartered at 10 Community Centre No. 2, Ashok Vihar Phase-II, New Delhi, India, the company markets its products domestically and exports to African countries including Congo, Benin, Togo, Senegal, Burkina Faso, Mozambique, Burundi, and Kenya, as well as CIS and SAARC nations like Kyrgyzstan, Philippines, and Myanmar, with registrations in 13 countries. In recent developments, Medicamen Organics completed the acquisition of Depot Pharmacy YEGO Ltd. in East Africa on October 8, 2024, to strengthen its regional presence; listed on the National Stock Exchange of India (NSE: MEDIORG) via an initial public offering in June 2024 raising INR 10.54 crores for international product registrations, plant upgrades focused on iron tablet capacity, working capital, and general corporate purposes; and announced a strategic investment and manufacturing collaboration with Medi Hub Organic Ltd. in Nepal in early 2025, involving technology transfer and joint procurement to expand into South Asia and the EU.